Related Experiment Video
Updated: Sep 23, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
Published on: December 26, 2011
Phosphoramidon potentiates the increase in lung resistance mediated by tachykinins in guinea pigs
1Lung Biology Center, San Francisco General Hospital, CA 94110.
Abstract:
This study was designed to evaluate the role of endogenous enkephalinase in regulating bronchoconstrictor responses in guinea pigs. We evaluated the effects of phosphoramidon, an enkephalinase inhibitor, on the increases in lung resistance (RL) caused by exogenous substance P and inhaled capsaicin (an agent thought to provoke bronchoconstriction in guinea pigs by stimulating the release of tachykinins from afferent nerve endings). In 6 of 6 animals, phosphoramidon potentiated the substance P-induced increase in RL (RL increased 380 +/- 100% [mean +/- SEM] before phosphoramidon and 1,300 +/- 400% afterward, p less than 0.025). In 4 of 4 animals, the repeated administration of a single dose of substance P after saline did not result in potentiation of the increase in RL caused by substance P. Similarly, in 6 animals exposed to inhaled capsaicin, phosphoramidon significantly increased capsaicin responsiveness when compared to 6 capsaicin-exposed animals not treated with phosphoramidon. Phosphoramidon-induced augmentation of the airway responsiveness to substance P and to capsaicin was not simply the result of a nonspecific increase in airway smooth muscle responsiveness because phosphoramidon failed to potentiate the bronchoconstrictor response to inhaled acetylcholine. These results suggest the enkephalinase plays an important role in modulating in vivo bronchoconstrictor responses to substance P in guinea pigs. Therefore, alterations in enkephalinase activity could contribute to in vivo alterations in bronchoconstrictor responsiveness.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Two...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

